CYPROTEX GETS DUAL BOOST FOR RESEARCH DEVELOPMENT.

Cyprotex plc (LSE: CRX), Macclesfield, England, the drug discovery technology and information company, has received peer-approved publication of its "virtual human and rat" system, known as Cloe PK(R). The details of extensive validation results for Cloe PK(R) showing how the technology can estimate blood levels of new drugs without the use of animals, have been accepted for publication by "Drug Metabolism and Disposition", a prestigious peer-reviewed journal encompassing work in this scientific area.

Cyprotex has also been awarded a grant by The Department of Trade & Industry (DTI) to extend the group's predictive technologies used in the invention of new drugs. This news follows a recent announcement that Cyprotex is forming its own research group, Cyprotex Research Ltd, which will be aimed at eradicating drug liabilities from the very earliest stages of drug discovery. The research group, which will be headed by Dr David Leahy, Cyprotex's founder and chief technical officer, will form academic and industrial collaborations to develop computational capabilities, to facilitate R&D productivity improvements throughout the industry. New tools and capabilities developed via the research group will be commercialized and offered to Cyprotex's pharmaceutical and biotechnology partners.

Dr Leahy said "Peer-reviewed acceptance of our work on Cloe PK(R) is an important landmark and a clear endorsement of Cyprotex's scientific excellence. This technology, along with new methodologies which we will develop as a result of the DTI grant, will help us to make the next step in our drive towards understanding and eradicating the problems associated with how new drugs are processed by the body."

Cyprotex is a specialist provider of experimental and computational capabilities to support ADME/toxicity and pharmacokinetics assessment for drug discovery partners. Its core products include the Cloe Screen(R) in vitro ADME/toxicity service, and Cloe PK(R) - a pharmacokinetics prediction system which integrates core ADME and physicochemical compound data to predict compound levels in plasma and major organs in the body. This unique combination of technologies is aimed at improving pharmaceutical productivity by improving the quality of compound libraries and drug candidates progressing through the drug pipeline. Cyprotex is listed on the London Stock Exchange (LSE: CRX).

For more information, call http://www.cyprotex.com.